{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
BioMarin Pharmaceutical, Inc.
BioMarin Pharmaceutical Hits New 52-Week High at USD 69.27
BioMarin Pharmaceutical, Inc. achieved a new 52-week high of USD 69.27 on August 10, 2026, despite a one-year performance decline of 16.95%. The company, with a market cap of USD 10,412 million, has a P/E ratio of 14.00 and a return on equity of 11.94%.
BioMarin Pharmaceutical Hits Day High with 8.63% Surge in Stock Price
BioMarin Pharmaceutical, Inc. saw a notable increase in its stock today, contrasting with the broader market's modest gains. While the company has shown recent weekly growth, its longer-term performance reflects challenges, including declines in both year-to-date and three-year metrics, alongside significant changes in profitability.
BioMarin Pharmaceutical Hits Day High with 7.77% Surge in Stock Price
BioMarin Pharmaceutical, Inc. has seen a significant rise in its stock today, outperforming the S&P 500. Despite recent gains, the company has struggled over longer periods, with notable declines year-to-date and over three years. Financially, it reports strong profit growth and healthy cash flow, though it trades at a premium valuation.
Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?
As of October 17, 2025, BioMarin Pharmaceutical, Inc. is fairly valued with a P/E ratio of 20 and a low PEG ratio of 0.14, but it has underperformed the S&P 500 significantly, with a year-to-date return of -18.93% compared to the index's 13.30%.
BioMarin Pharmaceutical, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
BioMarin Pharmaceutical, Inc. has recently adjusted its valuation, reflecting a reassessment of its financial metrics within the pharmaceuticals and biotechnology sector. The company shows competitive valuation ratios compared to peers, although its stock performance has faced challenges, with notable declines over the past year.
Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?
As of October 17, 2025, BioMarin Pharmaceutical, Inc. is fairly valued with a P/E ratio of 20 and a low PEG ratio of 0.14, indicating competitive positioning compared to peers like Illumina and Elanco, despite lacking specific return data.
Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?
As of October 17, 2025, BioMarin Pharmaceutical, Inc. is fairly valued with a P/E ratio of 20 and a low PEG ratio of 0.14, positioning it competitively among peers despite a year-to-date return of -18.93%, significantly trailing the S&P 500's 13.30%.
BioMarin Pharmaceutical Hits 52-Week Low at USD 51.56 Amid Decline
BioMarin Pharmaceutical, Inc. has reached a new 52-week low, trading at USD 51.56. The company has experienced a significant stock price decline over the past year, with a market capitalization of approximately USD 10.83 billion. Key financial metrics include a P/E ratio of 20.00 and a return on equity of 11.84%.
BioMarin Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Challenges
BioMarin Pharmaceutical, Inc. has recently revised its evaluation amid challenging market conditions. The stock price has seen a slight increase, but the company has struggled over the past year and three years, significantly underperforming compared to the S&P 500, indicating the need for strategic adjustments.
Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?
As of October 3, 2025, BioMarin Pharmaceutical, Inc. shows a mildly bearish technical trend with mixed signals across indicators, underperforming the S&P 500 year-to-date by -15.40% compared to its 14.18% gain.
Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?
As of October 3, 2025, BioMarin Pharmaceutical, Inc. exhibits a mildly bearish technical trend, with mixed indicators across various time frames and significant underperformance compared to the S&P 500.
Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?
As of October 3, 2025, BioMarin Pharmaceutical, Inc. shows a mildly bearish technical trend, with mixed signals from MACD and Bollinger Bands, and has underperformed the S&P 500 year-to-date by -15.67%.
BioMarin Pharmaceutical Hits New 52-Week Low at $52.48
BioMarin Pharmaceutical, Inc. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company, with a market capitalization of approximately USD 10.8 billion, has a P/E ratio of 20.00 and a return on equity of 11.84%.
Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?
As of September 8, 2025, BioMarin Pharmaceutical, Inc. is in a bearish trend with weak strength, underperforming the S&P 500 significantly with a year-to-date return of -16.11% compared to the S&P 500's 12.22%.
Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?
As of July 7, 2025, BioMarin Pharmaceutical, Inc. is fairly valued with a P/E ratio of 20 and has underperformed the S&P 500, showing a year-to-date return of -16.11% compared to the index's 12.22%.
Is BioMarin Pharmaceutical, Inc. overvalued or undervalued?
As of May 2, 2025, BioMarin Pharmaceutical is fairly valued with a P/E ratio of 20, but has underperformed the S&P 500 with a year-to-date decline of 17.72%, indicating potential growth challenges despite its lower valuation compared to peers.
Is BioMarin Pharmaceutical, Inc. technically bullish or bearish?
As of May 5, 2025, BioMarin Pharmaceutical, Inc. is in a bearish trend supported by multiple indicators, including bearish MACD and Bollinger Bands on weekly and monthly charts, along with underperformance compared to the S&P 500.
Who are in the management team of BioMarin Pharmaceutical, Inc.?
As of March 2022, the management team of BioMarin Pharmaceutical, Inc. includes CEO Jean-Jacques Bienaime and Lead Independent Director Richard Meier, along with independent directors Elizabeth Anderson, Willard Dere, Michael Grey, and Elaine Heron.
What does BioMarin Pharmaceutical, Inc. do?
BioMarin Pharmaceutical, Inc. is a biotechnology company that develops and commercializes pharmaceuticals for various diseases. As of March 2025, it reported net sales of $733 million and a market cap of approximately $10.55 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
